AI assistant
Sending…
SOLESENCE, INC. — Director's Dealing 2006
Dec 14, 2006
33563_dirs_2006-12-14_5c9d04de-6810-4f42-88bb-765a87b90359.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NANOPHASE TECHNOLOGIES CORPORATION (NANX)
CIK: 0000883107
Period of Report: 2006-12-12
Reporting Person: SIEGEL RICHARD W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2006-12-12 | Common Stock | G | 22915 | $0.00 | Disposed | 0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 209457 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $5.25 | 2008-06-10 | Common Stock (2000) | 2000 | Direct |
| Stock Option (right to buy) | $3.8125 | 2008-07-31 | Common Stock (11600) | 11600 | Direct |
| Stock Option (right to buy) | $9.92 | 2011-06-05 | Common Stock (2000) | 2000 | Direct |
| Stock Option (right to buy) | $3.78 | 2012-11-25 | Common Stock (2000) | 2000 | Direct |
| Stock Option (right to buy) | $5.07 | 2013-06-26 | Common Stock (2000) | 2000 | Direct |
| Deferred Common Stock | $ | Common Stock (3754) | 3754 | Direct |
Footnotes
F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
F2: Subject to certain restrictions, beginning on this date, options vest in five equal installments.
F3: Each share of deferred common stock represents a right to receive one share of common stock.
F4: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
More from SOLESENCE, INC.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 23
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Director's Dealing
2025
Dec 30
Director's Dealing
2025
Dec 11
Regulatory Filings
2025
Dec 2
Regulatory Filings
2025
Dec 1